Zura Bio Ltd. has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will replace Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors, previously serving in roles at Atara Biotherapeutics and Amgen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.